Endocrinology and Metabolism

Review Article

Thyroid
Ultrasound Imaging Criteria and Protocols for Active Surveillance of Low-Risk Thyroid Cancer: A Review of International Consensus Guidelines: Ji Ye Lee, Dong Gyu Na; Endocrinol Metab. 2025;40(2):185-194. Published online March 27, 2025; DOI: https://doi.org/10.3803/EnM.2024.2319

711 View
98 Download

Abstract PDF PubReader ePub: Given the indolent nature and favorable outcomes of papillary thyroid microcarcinoma (PTMC), active surveillance (AS) has been adopted as an alternative management option to immediate surgery. However, the meticulous selection of patients based on individual and tumor-specific characteristics, as well as ultrasound (US) findings, is crucial in AS. Regular US monitoring is performed during AS to detect indicators of tumor progression, such as growth, the emergence of new US features suggestive of gross extrathyroidal extension, and lymph node metastasis. Thus, imaging-based evaluations play a pivotal role in guiding the decision to continue AS or proceed with surgical intervention. This review introduces the Korean Society of Thyroid Radiology (KSThR) guideline for the standardized US imaging of patients with low-risk PTMC under AS, which provide practical recommendations for tumor assessment during the initiation and follow-up phases of AS. This review compared the key features of the KSThR guideline with those of major international guidelines and identified the similarities and differences in imaging methodologies and follow-up strategies. The primary objective of this review is to support the broader implementation of AS and improve outcomes for patients with low-risk PTMC by emphasizing imaging protocols.

Original Articles

Prognostic Impact of Primary Tumor Size in Papillary Thyroid Carcinoma without Lymph Node Metastasis: Chae A Kim, Hye In Kim, Na Hyun Kim, Tae Yong Kim, Won Bae Kim, Jae Hoon Chung, Min Ji Jeon, Tae Hyuk Kim, Sun Wook Kim, Won Gu Kim; Received October 2, 2024 Accepted January 2, 2025 Published online February 25, 2025; DOI: https://doi.org/10.3803/EnM.2024.2199 [Epub ahead of print]

710 View
28 Download

Abstract PDF PubReader ePub: Background
We aimed to investigate the prognostic significance of primary tumor size in patients with pT1–T3a N0 M0 papillary thyroid carcinoma (PTC), minimizing the impact of confounding factors.
Methods
A multicenter retrospective study included 5,759 patients with PTC. Those with lymph node metastasis, gross extrathyroidal extension (ETE), and aggressive variants were excluded. Patients were categorized by primary tumor size (≤1, 1.1–2, 2.1–4, and >4 cm) and subdivided based on the presence of microscopic ETE (mETE).
Results
The median age was 48.0 years, and 87.5% were female. The median primary tumor size was 0.7 cm, with mETE identified in 43.7%. The median follow-up was 8.0 years, with an overall recurrent/persistent disease rate of 2.8%. Multivariate analysis identified male sex, larger tumor size, and the presence of mETE as significant prognostic risk factors. The 10-year recurrent/persistent disease rates for tumors ≤1, 1.1–2, 2.1–4, and >4 cm were 2.5%, 4.7%, 11.1%, and 6.0%, respectively. The 2.1–4 cm group had a significantly higher hazard ratio (HR), with the >4 cm group had the highest HR than the ≤1 cm group. Patients with mETE had a higher recurrent/persistent disease rate (4.5%) than those without, with rates by tumor size being 2.6%, 5.6%, 16.7%, and 8.2%.
Conclusion
Larger tumor size and the presence of mETE significantly increased the risk of recurrent/persistent disease in PTC. Patients with pT2–T3a N0 M0 PTC (>2 cm) had a recurrent/persistent disease risk exceeding 5%, warranting vigilant management.

Thyroid
Study Protocol of Expanded Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro-EXP): Jae Hoon Moon, Eun Kyung Lee, Wonjae Cha, Young Jun Chai, Sun Wook Cho, June Young Choi, Sung Yong Choi, A Jung Chu, Eun-Jae Chung, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Kyungsik Kim, Min Joo Kim, Su-jin Kim, Woochul Kim, Yoo Hyung Kim, Chang Yoon Lee, Ji Ye Lee, Kyu Eun Lee, Young Ki Lee, Hunjong Lim, Do Joon Park, Sue K. Park, Chang Hwan Ryu, Junsun Ryu, Jungirl Seok, Young Shin Song, Ka Hee Yi, Hyeong Won Yu, Eleanor White, Katerina Mastrocostas, Roderick J. Clifton-Bligh, Anthony Glover, Matti L. Gild, Ji-hoon Kim, Young Joo Park; Endocrinol Metab. 2025;40(2):236-246. Published online February 18, 2025; DOI: https://doi.org/10.3803/EnM.2024.2136

1,241 View
74 Download

Abstract PDF Supplementary Material PubReader ePub: Background
Active surveillance (AS) has emerged as a viable management strategy for low-risk papillary thyroid microcarcinoma (PTMC), following pioneering trials at Kuma Hospital and the Cancer Institute Hospital in Japan. Numerous prospective cohort studies have since validated AS as a management option for low-risk PTMC, leading to its inclusion in thyroid cancer guidelines across various countries. From 2016 to 2020, the Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro) enrolled 1,177 patients, providing comprehensive data on PTMC progression, sonographic predictors of progression, quality of life, surgical outcomes, and cost-effectiveness when comparing AS to immediate surgery. The second phase of MAeSTro (MAeSTro-EXP) expands AS to low-risk papillary thyroid carcinoma (PTC) tumors larger than 1 cm, driven by the hypothesis that overall risk assessment outweighs absolute tumor size in surgical decision-making.
Methods
This protocol aims to address whether limiting AS to tumors smaller than 1 cm may result in unnecessary surgeries for low-risk PTCs detected during their rapid initial growth phase. By expanding the AS criteria to include tumors up to 1.5 cm, while simultaneously refining and standardizing the criteria for risk assessment and disease progression, we aim to minimize overtreatment and maintain rigorous monitoring to improve patient outcomes.
Conclusion
This study will contribute to optimizing AS guidelines and enhance our understanding of the natural course and appropriate management of low-risk PTCs. Additionally, MAeSTro-EXP involves a multinational collaboration between South Korea and Australia. This cross-country study aims to identify cultural and racial differences in the management of low-risk PTC, thereby enriching the global understanding of AS practices and their applicability across diverse populations.

Thyroid
Association of the Preoperative Controlling Nutritional Status (CONUT) Score with Clinicopathological Characteristics in Patients with Papillary Thyroid Carcinoma: Doohwa Kim, Myungsoo Im, Soree Ryang, Mijin Kim, Yun Kyung Jeon, Sang Soo Kim, Bo Hyun Kim; Endocrinol Metab. 2024;39(6):856-863. Published online November 15, 2024; DOI: https://doi.org/10.3803/EnM.2024.2006

1,009 View
63 Download

Abstract PDF Supplementary Material PubReader ePub: Background
The Controlling Nutritional Status (CONUT) score is an immunonutritional test tool based on serum albumin, total cholesterol, and lymphocyte counts. It has been studied as a simple prognostic predictor for various carcinomas. This study aimed to investigate the association between preoperative CONUT scores and the clinicopathological characteristics in papillary thyroid carcinoma (PTC) patients.
Methods
This study included 2,403 PTC patients who underwent total thyroidectomy between 2012 and 2016 at a single tertiary medical center. The CONUT scores were calculated based on preoperative blood tests. The clinicopathological characteristics were retrospectively reviewed. The patients were categorized by the CONUT score (relatively low, 0–2; relatively high, 3–5).
Results
Among the 2,997 PTC patients who underwent total thyroidectomy at Pusan National University Hospital between 2012 and 2016, those without preoperative blood test were excluded (n=149). Finally 2,403 patients were analyzed after excluding 439 patients taking lipid-lowering drugs and six patients without available T stage data after surgery. Based on the CONUT score, the relatively high score group had a lower body mass index (23.7±3.3 kg/m² vs. 21.9±2.9 kg/m², P<0.001), more advanced T stage (T stage 3/4, 5.9% vs. 11.4%, P=0.045), and higher extrathyroidal extension (2.1% vs. 7.6%, P=0.005).
Conclusion
Patients included in this large, single-center study all had a preoperative CONUT score of 0–5, but this study demonstrated that higher preoperative CONUT scores were significantly associated with advanced T stage and extrathyroidal extension. The CONUT score, which can be easily used in clinical practice, is thought to be helpful in predicting the aggressiveness of PTC.

Thyroid
Utilizing Immunoglobulin G4 Immunohistochemistry for Risk Stratification in Patients with Papillary Thyroid Carcinoma Associated with Hashimoto Thyroiditis: Faridul Haq, Gyeongsin Park, Sora Jeon, Mitsuyoshi Hirokawa, Chan Kwon Jung; Endocrinol Metab. 2024;39(3):468-478. Published online May 20, 2024; DOI: https://doi.org/10.3803/EnM.2024.1923

2,905 View
77 Download
1 Web of Science
1 Crossref

Abstract PDF PubReader ePub

Background
Hashimoto thyroiditis (HT) is suspected to correlate with papillary thyroid carcinoma (PTC) development. While some HT cases exhibit histologic features of immunoglobulin G4 (IgG4)-related disease, the relationship of HT with PTC progression remains unestablished.
Methods
This cross-sectional study included 426 adult patients with PTC (≥1 cm) undergoing thyroidectomy at an academic thyroid center. HT was identified based on its typical histologic features. IgG4 and IgG immunohistochemistry were performed. Wholeslide images of immunostained slides were digitalized. Positive plasma cells per 2 mm² were counted using QuPath and a pre-trained deep learning model. The primary outcome was tumor structural recurrence post-surgery.
Results
Among the 426 PTC patients, 79 were diagnosed with HT. With a 40% IgG4 positive/IgG plasma cell ratio as the threshold for diagnosing IgG4-related disease, a cutoff value of >150 IgG4 positive plasma cells per 2 mm² was established. According to this criterion, 53% (43/79) of HT patients were classified as IgG4-related. The IgG4-related HT subgroup presented a more advanced cancer stage than the IgG4-non-related HT group (P=0.038). The median observation period was 109 months (range, 6 to 142). Initial assessment revealed 43 recurrence cases. Recurrence-free survival periods showed significant (P=0.023) differences, with patients with IgG4 non-related HT showing the longest period, followed by patients without HT and those with IgG4-related HT.
Conclusion
This study effectively stratified recurrence risk in PTC patients based on HT status and IgG4-related subtypes. These findings may contribute to better-informed treatment decisions and patient care strategies.

Citations

Citations to this article as recorded by

Advanced pathological subtype classification of thyroid cancer using efficientNetB0
Hongpeng Guo, Junjie Zhang, You Li, Xinghe Pan, Chenglin Sun
Diagnostic Pathology.2025;[Epub] CrossRef

Thyroid
Clinicopathological Features and Molecular Signatures of Lateral Neck Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: Jinsun Lim, Han Sai Lee, Jin-Hyung Heo, Young Shin Song; Endocrinol Metab. 2024;39(2):324-333. Published online April 4, 2024; DOI: https://doi.org/10.3803/EnM.2023.1885

2,748 View
75 Download
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The predictive factors for lateral neck lymph node metastasis (LLNM) in papillary thyroid microcarcinoma (PTMC) remain undetermined. This study investigated the clinicopathological characteristics, transcriptomes, and tumor microenvironment in PTMC according to the LLNM status. We aimed to identify the biomarkers associated with LLNM development.
Methods
We retrospectively reviewed the medical records of patients with PTMC from two independent institutions between 2018 and 2022 (n=597 and n=467). We compared clinicopathological features between patients without lymph node metastasis (N0) and those with LLNM (N1b). Additionally, laser capture microdissection and RNA sequencing were performed on primary tumors from both groups, including metastatic lymph nodes from the N1b group (n=30; 20 primary tumors and 10 paired LLNMs). We corroborated the findings using RNA sequencing data from 16 BRAF-like PTMCs from The Cancer Genome Atlas. Transcriptomic analyses were validated by immunohistochemical staining.
Results
Clinicopathological characteristics, such as male sex, multifocality, extrathyroidal extension, lymphatic invasion, and central node metastasis showed associations with LLNM in PTMCs. Transcriptomic profiles between the N0 and N1b PTMC groups were similar. However, tumor microenvironment deconvolution from RNA sequencing and immunohistochemistry revealed an increased abundance of tumor-associated macrophages, particularly M2 macrophages, in the N1b group.
Conclusion
Patients with PTMC who have a male sex, multifocality, extrathyroidal extension, lymphatic invasion, and central node metastasis exhibited an elevated risk for LLNM. Furthermore, infiltration of M2 macrophages in the tumor microenvironment potentially supports tumor progression and LLNM in PTMCs.

Citations

Citations to this article as recorded by

Prediction of lymph node metastasis in papillary thyroid carcinoma using non-contrast CT-based radiomics and deep learning with thyroid lobe segmentation: A dual-center study
Hao Wang, Xuan Wang, Yusheng Du, You Wang, Zhuojie Bai, Di Wu, Wuliang Tang, Hanling Zeng, Jing Tao, Jian He
European Journal of Radiology Open.2025; 14: 100639. CrossRef

Thyroid
Active Surveillance for Low-Risk Papillary Thyroid Carcinoma as an Acceptable Management Option with Additional Benefits: A Comprehensive Systematic Review: Jee Hee Yoon, Wonsuk Choi, Ji Yong Park, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang; Endocrinol Metab. 2024;39(1):152-163. Published online January 22, 2024; DOI: https://doi.org/10.3803/EnM.2023.1794

5,266 View
193 Download
4 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Active surveillance (AS) has been introduced as a management strategy for low-risk papillary thyroid carcinoma (PTC) due to its typically indolent nature. Despite this, the widespread adoption of AS has encountered several challenges. The aim of this systematic review was to evaluate the safety of AS related to disease progression and its benefits compared with immediate surgery (IS).
Methods
Studies related to AS in patients with low-risk PTC were searched through the Ovid MEDLINE, Embase, Cochrane Library, and KoreaMed databases. Studies on disease progression, surgical complication, quality of life (QoL), and cost-effectiveness were separately analyzed and narratively synthesized.
Results
In the evaluation of disease progression, the proportions of cases with tumor growth ≥3 mm and a volume increase >50% were 2.2%–10.8% and 16.0%–25.5%, respectively. Newly detected lymph node metastasis was identified in 0.0%–1.4% of patients. No significant difference was found between IS and delayed surgery in surgical complications, including vocal cord paralysis and postoperative hypoparathyroidism. AS was associated with better QoL than IS. Studies on the cost-effectiveness of AS reported inconsistent data, but AS was more cost-effective when quality-adjusted life years were considered.
Conclusion
AS is an acceptable management option for patients with low-risk PTC based on the low rate of disease progression and the absence of an increased mortality risk. AS has additional benefits, including improved QoL and greater QoL-based cost-effectiveness.

Citations

Citations to this article as recorded by

Thyroid Nodules: Past, Present, and Future
Alan A. Parsa, Hossein Gharib
Endocrine Practice.2025; 31(1): 114. CrossRef
Approach to the Patient With Thyroid Cancer: Selection and Management of Candidates for Lobectomy
Eyal Robenshtok, Gideon Bachar, Amit Ritter
The Journal of Clinical Endocrinology & Metabolism.2025;[Epub] CrossRef
Navigating Active Surveillance for Low-Risk PTMC by Standardizing Ultrasound Evaluation: Key Takeaways from the Latest Korean Society of Thyroid Radiology Consensus Statements
Young Joo Park
Clinical Thyroidology®.2025; 37(1): 27. CrossRef
It Is Time to Understand the Additional Benefits of Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
Kyeong Jin Kim
Endocrinology and Metabolism.2024; 39(1): 95. CrossRef

Thyroid
Comparative Analysis of Driver Mutations and Transcriptomes in Papillary Thyroid Cancer by Region of Residence in South Korea: Jandee Lee, Seonhyang Jeong, Hwa Young Lee, Sunmi Park, Meesson Jeong, Young Suk Jo; Endocrinol Metab. 2023;38(6):720-729. Published online November 6, 2023; DOI: https://doi.org/10.3803/EnM.2023.1758

2,529 View
65 Download
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Radiation exposure is a well-known risk factor for papillary thyroid cancer (PTC). South Korea has 24 nuclear reactors in operation; however, no molecular biological analysis has been performed on patients with PTC living near nuclear power plants.
Methods
We retrospectively included patients with PTC (n=512) divided into three groups according to their place of residence at the time of operation: inland areas (n=300), coastal areas far from nuclear power plants (n=134), and nuclear power plant areas (n=78). After propensity score matching (1:1:1) by age, sex, and surgical procedure, the frequency of representative driver mutations and gene expression profiles were compared (n=50 per group). Epithelial-mesenchymal transition (EMT), BRAF, thyroid differentiation, and radiation scores were calculated and compared.
Results
No significant difference was observed in clinicopathological characteristics, including radiation exposure history and the frequency of incidentally discovered thyroid cancer, among the three groups. BRAF^V600E mutation was most frequently detected in the groups, with no difference among the three groups. Furthermore, gene expression profiles showed no statistically significant difference. EMT and BRAF scores were higher in our cohort than in cohorts from Chernobyl tissue bank and The Cancer Genome Atlas Thyroid Cancer; however, there was no difference according to the place of residence. Radiation scores were highest in the Chernobyl tissue bank but exhibited no difference according to the place of residence.
Conclusion
Differences in clinicopathological characteristics, frequency of representative driver mutations, and gene expression profiles were not observed according to patients’ region of residence in South Korea.

Citations

Citations to this article as recorded by

Systemic therapy for differentiated thyroid cancer with distant metastasis
Eun Kyung Lee
Journal of the Korean Medical Association.2024; 67(7): 484. CrossRef

Thyroid
Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma: Jinsun Lim, Han Sai Lee, Jiyun Park, Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho, Young Shin Song; Endocrinol Metab. 2023;38(4):445-454. Published online July 18, 2023; DOI: https://doi.org/10.3803/EnM.2023.1702

4,244 View
156 Download
7 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Papillary thyroid carcinoma (PTC) can be classified into two distinct molecular subtypes, BRAF-like (BL) and RASlike (RL). However, the molecular characteristics of each subtype according to clinicopathological factors have not yet been determined. We aimed to investigate the gene signatures and tumor microenvironment according to clinicopathological factors, and to identify the mechanism of progression in BL-PTCs and RL-PTCs.
Methods
We analyzed RNA sequencing data and corresponding clinicopathological information of 503 patients with PTC from The Cancer Genome Atlas database. We performed differentially expressed gene (DEG), Gene Ontology, and molecular pathway enrichment analyses according to clinicopathological factors in each molecular subtype. EcoTyper and CIBERSORTx were used to deconvolve the tumor cell types and their surrounding microenvironment.
Results
Even for the same clinicopathological factors, overlapping DEGs between the two molecular subtypes were uncommon, indicating that BL-PTCs and RL-PTCs have different progression mechanisms. Genes related to the extracellular matrix were commonly upregulated in BL-PTCs with aggressive clinicopathological factors, such as old age (≥55 years), presence of extrathyroidal extension, lymph node metastasis, advanced tumor-node-metastasis (TNM) stage, and high metastasis-age-completeness of resection- invasion-size (MACIS) scores (≥6). Furthermore, in the deconvolution analysis of tumor microenvironment, cancer-associated fibroblasts were significantly enriched. In contrast, in RL-PTCs, downregulation of immune response and immunoglobulin-related genes was significantly associated with aggressive characteristics, even after adjusting for thyroiditis status.
Conclusion
The molecular phenotypes of cancer progression differed between BL-PTC and RL-PTC. In particular, extracellular matrix and cancer-associated fibroblasts, which constitute the tumor microenvironment, would play an important role in the progression of BL-PTC that accounts for the majority of advanced PTCs.

Citations

Citations to this article as recorded by

Nuclear pseudoinclusion is associated with BRAFV600E mutation: Analysis of nuclear features in papillary thyroid carcinoma
Agnes Stephanie Harahap, Dina Khoirunnisa, Salinah, Maria Francisca Ham
Annals of Diagnostic Pathology.2025; 75: 152434. CrossRef
Transcriptome of Anaplastic Thyroid Cancer Reveals Two Molecular Subtypes with Distinct Tumor Microenvironment and Prognosis
Hyunjong Byun, Han Sai Lee, Young Shin Song, Young Joo Park
Thyroid®.2025; 35(4): 367. CrossRef
Allele frequency in thyroid cancer: mechanisms, challenges, and applications in cancer therapy
Jiayu Huang, Jiazhi Wang, Guangzhi Wang, Yongfu Zhao
Thyroid Research.2025;[Epub] CrossRef
Papillary Thyroid Cancer Remodels the Genetic Information Processing Pathways
Dumitru Andrei Iacobas, Sanda Iacobas
Genes.2024; 15(5): 621. CrossRef
A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma
Tahereh Haghzad, Babak Khorsand, S. Adeleh Razavi, Mehdi Hedayati
Endocrine.2024; 86(2): 707. CrossRef
Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements
Daisuke Uno, Kazuhira Endo, Tomomi Yoshikawa, Nobuyuki Hirai, Eiji Kobayashi, Yosuke Nakanishi, Satoru Kondo, Tomokazu Yoshizaki
Thyroid Research.2024;[Epub] CrossRef
Multi-objective genetic algorithm for multi-view feature selection
Vandad Imani, Carlos Sevilla-Salcedo, Elaheh Moradi, Vittorio Fortino, Jussi Tohka
Applied Soft Computing.2024; 167: 112332. CrossRef
Emerging Strategies for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Combining Immune Checkpoint Inhibitors with VEGF Inhibitors
Young Joo Park
Clinical Thyroidology®.2024; 36(10): 377. CrossRef

Thyroid
Diagnostic Performance of Thyroid Core Needle Biopsy Using the Revised Reporting System: Comparison with Fine Needle Aspiration Cytology: Kwangsoon Kim, Ja Seong Bae, Jeong Soo Kim, So Lyung Jung, Chan Kwon Jung; Endocrinol Metab. 2022;37(1):159-169. Published online February 28, 2022; DOI: https://doi.org/10.3803/EnM.2021.1299

6,072 View
209 Download
13 Web of Science
16 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We aim to validate the diagnostic performance of thyroid core needle biopsy (CNB) for diagnosing malignancy in clinical settings to align with the changes made in recently updated thyroid CNB guidelines.
Methods
We retrospectively analyzed 1,381 thyroid CNB and 2,223 fine needle aspiration (FNA) samples. The FNA and CNB slides were interpreted according to the Bethesda System for Reporting Thyroid Cytopathology and updated practice guidelines for thyroid CNB, respectively.
Results
Compared to FNA, CNB showed lower rates of inconclusive results: categories I (2.8% vs. 11.2%) and III (1.2% vs. 6.2%), and higher rates of categories II (60.9% vs. 50.4%) and IV (17.5% vs. 2.0%). The upper and lower bounds of the risk of malignancy (ROM) for category IV of CNB were 43.2% and 26.6%, respectively. The CNB subcategory IVb with nuclear atypia had a higher ROM than the subcategory without nuclear atypia (40%–62% vs. 23%–36%). In histologically confirmed cases, there was no significant difference in the diagnostic performance between CNB and FNA for malignancy. However, neoplastic diseases were more frequently detected by CNB than by FNA (88.8% vs. 77.6%, P=0.046). In category IV, there was no difference in unnecessary surgery rate between CNB and FNA (4.7% vs. 6.9%, P=0.6361).
Conclusion
Thyroid CNB decreased the rate of inconclusive results and showed a higher category IV diagnostic rate than FNA. The revised guidelines for thyroid CNB proved to be an excellent reporting system for assessing thyroid nodules.

Citations

Citations to this article as recorded by

Cytology fine-needle aspiration and surgical pathology core needle biopsy reporting: blurred lines or battle lines?
Paul A. VanderLaan
Journal of the American Society of Cytopathology.2025; 14(1): 1. CrossRef
PESI-MS combined with AI to build a prediction model for lymph node metastasis of papillary thyroid cancer
Qixin Huang, Zhenhe Chen, Lingyu Zhao, Lichao Jiang, Ye Wang, Qianqian Feng, Yajuan Lei, Xiaodong Li, Dingrong Zhong
Pathology - Research and Practice.2025; 270: 155952. CrossRef
Superior Diagnostic Yield of Core Needle Biopsy Over Fine Needle Aspiration in Diagnosing Follicular-Patterned Neoplasms: A Multicenter Study Focusing on Bethesda IV Results
Leehi Joo, Jung Hwan Baek, Jungbok Lee, Dong Eun Song, Sae Rom Chung, Young Jun Choi, Jeong Hyun Lee
Korean Journal of Radiology.2025;[Epub] CrossRef
Examining the impact of several factors including COVID‐19 on thyroid fine‐needle aspiration biopsy
Muzaffer Serdar Deniz, Merve Dindar
Diagnostic Cytopathology.2024; 52(1): 42. CrossRef
Consensus SFE-AFCE-SFMN 2022 sur la prise en charge des nodules thyroïdiens : intérêt et place de la cytologie thyroïdienne
Myriam Decaussin-Petrucci, Beatrix Cochand Priollet, Emannuelle Leteurtre, Frédérique Albarel, Françoise Borson-Chazot
Annales de Pathologie.2024; 44(1): 20. CrossRef
A comparative analysis of core needle biopsy and repeat fine needle aspiration in patients with inconclusive initial cytology of thyroid nodules
Xuejiao Su, Can Yue, Wanting Yang, Buyun Ma
Frontiers in Endocrinology.2024;[Epub] CrossRef
The Diagnostic Role of Repeated Biopsy of Thyroid Nodules with Atypia of Undetermined Significance with Architectural Atypia on Core-Needle Biopsy
Hye Hyeon Moon, Sae Rom Chung, Young Jun Choi, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee, Jung Hwan Baek
Endocrinology and Metabolism.2024; 39(2): 300. CrossRef
Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules 2024
Young Joo Park, Eun Kyung Lee, Young Shin Song, Su Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung,
International Journal of Thyroidology.2024; 17(1): 208. CrossRef
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 2. Surgical Management of Thyroid Cancer 2024
Yoon Young Cho, Cho Rok Lee, Ho-Cheol Kang, Bon Seok Koo, Hyungju Kwon, Sun Wook Kim, Won Woong Kim, Jung-Han Kim, Dong Gyu Na, Young Joo Park, Kyorim Back, Young Shin Song, Seung Hoon Woo, Ho-Ryun Won, Chang Hwan Ryu, Jee Hee Yoon, Min Kyoung Lee, Eun Ky
International Journal of Thyroidology.2024; 17(1): 30. CrossRef
Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis
Chao Qin, Sijia Cai, Yanyu Qi, Meilin Liu, Weibo Xu, Min Yin, Haitao Tang, Qinghai Ji, Tian Liao, Yu Wang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Current role of interventional radiology in thyroid nodules
Onur Taydas, Erbil Arik, Omer Faruk Sevinc, Ahmet Burak Kara, Mustafa Ozdemir, Hasret Cengiz, Zulfu Bayhan, Mehmet Halil Ozturk
Frontiers in Endocrinology.2024;[Epub] CrossRef
A simplified four-tier classification for thyroid core needle biopsy
M. Paja, J. L. Del Cura, R. Zabala, I. Korta, Mª T. Gutiérrez, A. Expósito, A. Ugalde
Journal of Endocrinological Investigation.2024; 48(4): 895. CrossRef
Preoperative Risk Stratification of Follicular-patterned Thyroid Lesions on Core Needle Biopsy by Histologic Subtyping and RAS Variant-specific Immunohistochemistry
Meejeong Kim, Sora Jeon, Chan Kwon Jung
Endocrine Pathology.2023; 34(2): 247. CrossRef
2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
International Journal of Thyroidology.2023; 16(1): 1. CrossRef
Reevaluating diagnostic categories and associated malignancy risks in thyroid core needle biopsy
Chan Kwon Jung
Journal of Pathology and Translational Medicine.2023; 57(4): 208. CrossRef
A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model
Faridul Haq, Andrey Bychkov, Chan Kwon Jung
Endocrine Pathology.2022; 33(4): 472. CrossRef

Thyroid
Association between Iodine Intake, Thyroid Function, and Papillary Thyroid Cancer: A Case-Control Study: Kyungsik Kim, Sun Wook Cho, Young Joo Park, Kyu Eun Lee, Dong-Wook Lee, Sue K. Park; Endocrinol Metab. 2021;36(4):790-799. Published online August 11, 2021; DOI: https://doi.org/10.3803/EnM.2021.1034

6,845 View
278 Download
16 Web of Science
19 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study aimed to assess the effects of iodine intake, thyroid function, and their combined effect on the risk of papillary thyroid cancer (PTC) and papillary thyroid microcarcinoma (PTMC).
Methods
A case-control study was conducted including 500 community-based controls who had undergone a health check-up, and 446 overall PTC cases (209 PTC and 237 PTMC) from the Thyroid Cancer Longitudinal Study. Urinary iodine concentration (UIC), was used as an indicator of iodine intake, and serum for thyroid function. The risk of PTC and PTMC was estimated using unconditional logistic regression.
Results
Excessive iodine intake (UIC ≥220 μg/gCr) was associated with both PTC (odds ratio [OR], 18.13 95% confidence interval [CI], 8.87 to 37.04) and PTMC (OR, 8.02; 95% CI, 4.64 to 13.87), compared to adequate iodine intake (UIC, 85 to 219 μg/gCr). Free thyroxine (T4) levels ≥1.25 ng/dL were associated with PTC (OR, 1.97; 95% CI, 1.36 to 2.87) and PTMC (OR, 2.98; 95% CI, 2.01 to 4.41), compared to free T4 levels of 0.7 to 1.24 ng/dL. Individuals with excessive iodine intake and high free T4 levels had a greatly increased OR of PTC (OR, 43.48; 95% CI, 12.63 to 149.62), and PTMC (OR, 26.96; 95% CI, 10.26 to 70.89), compared to individuals with adequate iodine intake and low free T4 levels.
Conclusion
Excessive iodine intake using creatinine-adjusted UIC and high free T4 levels may have a synergistic effect on PTC and PTMC. Considering both iodine intake and thyroid function is important to assess PTC and PTMC risk.

Citations

Citations to this article as recorded by

Continued rise in the incidence of thyroid cancer in Iran: true increase or overdiagnosis?
Mahnaz Pejman Sani, Shahrzad Mohseni, Hilda Samimi, Shirzad Nasiri, Babak Fallahi, Mohammadreza Mohajeri-Tehrani, Seyed Mohammad Tavangar, Mahmood Naderi, Nooshin Shirzad, Bagher Larijani, Sayed Mahmoud Sajjadi-Jazi, Gholamreza Roshandel, Vahid Haghpanah
Journal of Diabetes & Metabolic Disorders.2025;[Epub] CrossRef
Heavy metals in seaweed: Implications for health benefits, risks, and safety regulations
Lori Huang, Ji-Young Lee, Young-Ki Park, Jaeeun Lee
Journal of Agriculture and Food Research.2025; 21: 101830. CrossRef
Risks of Iodine Excess
Seo Young Sohn, Kosuke Inoue, Connie M Rhee, Angela M Leung
Endocrine Reviews.2024; 45(6): 858. CrossRef
The influence of micronutrients and macronutrients excess or deficiency on thyroid function
K. Brzdęk, S. Wiśniewski, O. Domańska, W. Baran, M. Brzdęk
The Ukrainian Biochemical Journal.2024; 96(4): 5. CrossRef
Association between Thyroid Profile Levels and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Retrospective Study
Yu-Shan Hsieh, Ting-Teng Yang, Chung-Huei Hsu, Yan-Yu Lin
Reports.2024; 7(3): 78. CrossRef
Consequences of acute and long‐term excessive iodine intake: A literature review focusing on seaweed as a potential dietary iodine source
Marthe Jordbrekk Blikra, Inger Aakre, Jessica Rigutto‐Farebrother
Comprehensive Reviews in Food Science and Food Safety.2024;[Epub] CrossRef
Iodine Excess Is Associated with Thyroid Dysfunction Among the Elderly
Qi Jin, Zhangzhao Wang, Junjing Li, Hexi Zhang, Mengxin Liu, Chunxi Wang, Wenxing Guo, Wanqi Zhang
Biological Trace Element Research.2024;[Epub] CrossRef
Association between urinary iodine concentration and the risk of papillary thyroid cancer by sex and age: a case–control study
Yerin Hwang, Hyun-Kyung Oh, Jae Hoon Chung, Sun Wook Kim, Jung-Han Kim, Jee Soo Kim, Myung-Hee Shin
Scientific Reports.2023;[Epub] CrossRef
Association between iodine nutrition and cervical lymph node metastasis of papillary thyroid microcarcinoma
Hengqiang Zhao, Jin Hu, Le Cui, Yiping Gong, Tao Huang
Frontiers in Endocrinology.2023;[Epub] CrossRef
Sex-specific Associations between Body Mass Index and Thyroid Cancer Incidence among Korean Adults
Kyoung-Nam Kim, Kyungsik Kim, Sangjun Lee, Sue K. Park
Cancer Epidemiology, Biomarkers & Prevention.2023; 32(9): 1227. CrossRef
Nomogram Model Based on Iodine Nutrition and Clinical Characteristics of Papillary Thyroid Carcinoma to Predict Lateral Lymph Node Metastasis
Junrong Wang, Yuzhang Gao, Yuxuan Zong, Weitong Gao, Xueying Wang, Ji Sun, Susheng Miao
Cancer Control.2023;[Epub] CrossRef
Content of Copper, Iron, Iodine, Rubidium, Strontium and Zinc in Thyroid Malignant Nodules and Thyroid Tissue adjacent to Nodules
Vladimir Zaichick, Qiping Dong
Journal of Clinical and Diagnostic Pathology.2022; 1(4): 7. CrossRef
Distinguish Thyroid Malignant from Benign Alterations using Trace Element Contents in Nodular Tissue determined by Neutron Activation and Inductively Coupled Plasma Mass Spectrometry
Vladimir Zaichick
Journal of Clinical and Diagnostic Pathology.2022; 1(4): 18. CrossRef
Seaweed and Iodine Intakes and SLC5A5 rs77277498 in Relation to Thyroid Cancer
Tung Hoang, Eun Kyung Lee, Jeonghee Lee, Yul Hwangbo, Jeongseon Kim
Endocrinology and Metabolism.2022; 37(3): 513. CrossRef
Iodine nutrition and papillary thyroid cancer
Xueqi Zhang, Fan Zhang, Qiuxian Li, Chuyao Feng, Weiping Teng
Frontiers in Nutrition.2022;[Epub] CrossRef
The relationship between urinary iodine concentration and papillary thyroid cancer: A systematic review and meta-analysis
Xueqi Zhang, Fan Zhang, Qiuxian Li, Renaguli Aihaiti, Chuyao Feng, Deshi Chen, Xu Zhao, Weiping Teng
Frontiers in Endocrinology.2022;[Epub] CrossRef
Screening and validation of lymph node metastasis risk-factor genes in papillary thyroid carcinoma
Qiaoyue Zhang, Jing Li, Hengyan Shen, Xinyu Bai, Tao Zhang, Ping Liu
Frontiers in Endocrinology.2022;[Epub] CrossRef
Diagnosis of Thyroid Malignancy using Levels of Chemical Element Contents in Nodular Tissue
Vladimir Zaichick
Journal of Health Care and Research.2022; 3(1): 16. CrossRef
Associations of Habitual Mineral Intake with New-Onset Prediabetes/Diabetes after Acute Pancreatitis
Claire F. Norbitt, Wandia Kimita, Juyeon Ko, Sakina H. Bharmal, Maxim S. Petrov
Nutrients.2021; 13(11): 3978. CrossRef

Clinical Study
Mechanisms of the Impact of Hashimoto Thyroiditis on Papillary Thyroid Carcinoma Progression: Relationship with the Tumor Immune Microenvironment: Oksana Sulaieva, Olena Chernenko, Oleksiy Selesnov, Oleksandr Nechay, Oleksandr Maievskyi, Tetyana Falalyeyeva, Nazarii Kobyliak, Olena Tsyryuk, Yurii Penchuk, Dmytro Shapochka; Endocrinol Metab. 2020;35(2):443-455. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.443

8,353 View
187 Download
20 Web of Science
21 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
The relationship between Hashimoto thyroiditis (HT) and papillary thyroid carcinoma (PTC) remains uncertain. We assessed the impact of HT on the tumor immune microenvironment (TIME) in PTC.
Methods
Thirty patients with PTC (group 1) and 30 patients with PTC and HT (group 2) were enrolled in this pilot study. The distribution and number of CD8+ lymphocytes, plasma cells (CD138+), regulatory T cells (forkhead box P3 [FOXP3+)], mast cell tryptase (MCT+), and M2 macrophages (CD163+) were evaluated. To test the hypothesis that HT impacts PTC development via signal transducer and activator of transcription 6 (STAT6) activation and M2 macrophage polarization, we investigated STAT6 expression in tumor and stromal cells. We also evaluated vascular endothelial growth factor (VEGF) expression by lymph node metastasis (LNM) status.
Results
TIME showed significant between-group differences. Group 1 patients demonstrated immune desert or immune-excluded immunophenotypes, while an inflamed phenotype with more CD8+ cells (P<0.001) predominated in group 2. Immune-excluded TIME was associated with the highest LNM rate. In PTC, LNM was associated with more numerous CD163+ cells. Moreover, LNM in group 1 was associated with increased numbers of mast cells peritumorally and FOXP3+ cells intratumorally and peritumorally. Group 2 demonstrated higher STAT6 but not higher VEGF expression in tumor cells. High VEGF expression was associated with LNM regardless of HT status.
Conclusion
Concomitant HT impacted PTC signaling via STAT6 and TIME by increasing the number of CD8+ cells. LNM is associated with increases in CD163+ cells and VEGF expression in PTC, whereas HT affected LNM through different mechanisms.

Citations

Citations to this article as recorded by

Immune cells in thyroid adenoma and carcinoma: uncovering a hidden value of assessing tumor-host interplay and its potential application in thyroid cytopathology
Iryna Omelianenko, Nazarii Kobyliak, Tetyana Falalyeyeva, Oleksii Seleznov, Pavlina Botsun, Lyudmila Ostapchenko, Oleksandr Korotkyi, Liudmyla Domylivska, Olena Tsyryuk, Galyna Mykhalchyshyn, Tetiana Shapochka, Oksana Sulaieva
Frontiers in Molecular Biosciences.2025;[Epub] CrossRef
Exploring the mechanism of vitamin C on the co-expressed genes of papillary thyroid carcinoma and Epstein-Barr virus based on bioinformatics, network pharmacology and molecular docking analysis
Dongliang Shi, Liang Chen, Chenhao Li, Meng Yang, Wenhua Yang, Guozhong Cui, Jinzhao Liu, Qianqian Chen
Discover Oncology.2025;[Epub] CrossRef
Papillary thyroid carcinoma with Hashimoto’s thyroiditis: impact and correlation
Shengpeng Yao, Hong Zhang
Frontiers in Endocrinology.2025;[Epub] CrossRef
Mechanisms underlying the promotion of papillary thyroid carcinoma occurrence and progression by Hashimoto’s thyroiditis
Xiaohui Xue, Deqi Wu, Hangyu Yao, Kainan Wang, Zhengtao Liu, Haijiang Qu
Frontiers in Endocrinology.2025;[Epub] CrossRef
Research Progress on the Immunological Correlation Between Papillary Thyroid Carcinoma and Hashimoto’s Thyroiditis
Digui Fang, Limei Zhou, Biao Zheng, Ran Wang
Journal of Immunology Research.2025;[Epub] CrossRef
The impact of Hashimoto’s thyroiditis on the clinical outcome of papillary thyroid cancer after radioactive iodine therapy: a propensity score matching study
Jingjia Cao, Yaru Sun, Yang Liu, Yunfei Xu, Xiao Li, Wei Zhang, Ximing Wang
Endocrine.2024; 87(1): 178. CrossRef
Prognostic role of STAT6 in patients with non-small cell lung cancer
O. Vynnychenko, Y. Moskalenko, O. Yazykov, I. Tymchenko, O. Seleznov, O. Sulaieva, R. Moskalenko
Regulatory Mechanisms in Biosystems.2024; 15(4): 868. CrossRef
Clinical significance and diagnostic value of QPCT, SCEL and TNFRSF12A in papillary thyroid cancer
Tairong Liang, Xiuqian Wu, Lan Wang, Zhengzhong Ni, Ying Fan, Peishan Wu, Hongzhi Wang, Yongdong Niu, Haihua Huang
Pathology - Research and Practice.2023; 245: 154431. CrossRef
Recommend with caution: A meta-analysis investigating papillary thyroid carcinoma tumor progression under active surveillance
Peter P. Issa, Ruhul Munshi, Aaron L. Albuck, Mahmoud Omar, Ruba F. Abu Alhuda, Tyler Metz, Mohammad Hussein, Mohamed Shama, Grace S. Lee, Eman Toraih, Emad Kandil
American Journal of Otolaryngology.2023; 44(6): 103994. CrossRef
Hashimoto's thyroiditis is negatively associated with lymph node metastasis in PTMC
Hui Huang, Siyuan Xu, Song Ni, Wensheng Liu, Shaoyan Liu
Journal of Cancer Research and Clinical Oncology.2023; 149(17): 15525. CrossRef
A nomogram based on the risk factors of cervical lymph node metastasis in papillary thyroid carcinoma coexistent with Hashimoto’s thyroiditis
Huanhuan Miao, Jingwen Zhong, Xuesha Xing, Jiawei Sun, Jiaqi Wu, Chengwei Wu, Yan Yuan, Xianli Zhou, Hongbo Wang
Clinical Hemorheology and Microcirculation.2023; 85(3): 235. CrossRef
The role of vascular endothelial growth factor in the development of papillary thyroid carcinoma in patients with lymphocytic thyroiditis
Nese E. GULCELIK, Safak AKIN, Kadriye AYDIN, Cisel AYDIN MERICOZ, Yesim G. GULER TEZEL, Aydan USMAN
Minerva Endocrinology.2023;[Epub] CrossRef
Identification of Transcriptional Pattern Related to Immune Cell Infiltration With Gene Co-Expression Network in Papillary Thyroid Cancer
Meiye Li, Jimei Zhang, Zongjing Zhang, Ying Qian, Wei Qu, Zhaoshun Jiang, Baochang Zhao
Frontiers in Endocrinology.2022;[Epub] CrossRef
A Potential Nine-lncRNAs Signature Identification and Nomogram Diagnostic Model Establishment for Papillary Thyroid Cancer
Jin-Ming Yao, Jun-Yu Zhao, Fang-Fang Lv, Xue-Bo Yang, Huan-Jun Wang
Pathology and Oncology Research.2022;[Epub] CrossRef
Hyperhomocysteinemia in the pathogenesis of cardiovascular and endocrine diseases: translational messages
Rostyslav KAMINSKY, Andrii YANCHYSHYN, Natalia BELEMETS, Olena KURYK, Inga SAMBORSKA, Iryna DZEVULSKA, Rinaldo PELLICANO
Minerva Biotechnology and Biomolecular Research.2022;[Epub] CrossRef
Immune Microenvironment of Muscular-Invasive Urothelial Carcinoma: The Link to Tumor Immune Cycle and Prognosis
Oleksandr Stakhovskyi, Nazarii Kobyliak, Oleg Voylenko, Eduard Stakhovskyi, Roman Ponomarchuk, Oksana Sulaieva
Cells.2022; 11(11): 1802. CrossRef
Comprehensive analysis of lncRNA-mediated ceRNA regulatory networks and key genes associated with papillary thyroid cancer coexistent with Hashimoto’s thyroiditis
Yuepeng Zhang, Yueli Tian
BMC Endocrine Disorders.2022;[Epub] CrossRef
Research Progress in the Correlation between AID, BRAFV600E and Papillary Thyroid Carcinoma
鑫焦
Advances in Clinical Medicine.2022; 12(12): 11503. CrossRef
STAT6: A review of a signaling pathway implicated in various diseases with a special emphasis in its usefulness in pathology
Georgia Karpathiou, Alexandra Papoudou-Bai, Elise Ferrand, Jean Marc Dumollard, Michel Peoc’h
Pathology - Research and Practice.2021; 223: 153477. CrossRef
Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes
Siyuan Xu, Hui Huang, Jiaxin Qian, Yang Liu, Ying Huang, Xiaolei Wang, Shaoyan Liu, Zhengang Xu, Jie Liu
JAMA Network Open.2021; 4(7): e2118526. CrossRef
LARINGOPHARINGEAL REFLUX IMPACTS IMMUNE MICROENVIRONMENT OF LARYNGEAL CARCINOMA
D.I. Zabolotnyi, V.V. Kizim, D.D. Zabolotna, Y.V. Kizim, O.N. Sulaieva
Fiziolohichnyĭ zhurnal.2020; 66(4): 12. CrossRef

Clinical Study
Development and Validation of a Risk Scoring System Derived from Meta-Analyses of Papillary Thyroid Cancer: Sunghwan Suh, Tae Sik Goh, Yun Hak Kim, Sae-Ock Oh, Kyoungjune Pak, Ju Won Seok, In Joo Kim; Endocrinol Metab. 2020;35(2):435-442. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.435; Correction in: Endocrinol Metab 2023;38(2):287

6,977 View
141 Download
4 Web of Science
3 Crossref

Abstract PDF PubReader ePub

Background
The aim of this study was to develop a scoring system to stratify the risk of papillary thyroid cancer (PTC) and to select the proper management.
Methods
We performed a systematic search of MEDLINE and Embase. Data regarding patients’ prognoses were obtained from the included studies. Odds ratios (ORs) with statistical significance were extracted from the publications. To generate a risk scoring system (RSS), ORs were summed (RSS1), and summed after natural-logarithmic transformation (RSS2). RSS1 and RSS2 were compared to the eighth edition of the American Joint Committee on Cancer (AJCC) staging system and the 2015 American Thyroid Association (ATA) guidelines for thyroid nodules and differentiated thyroid carcinoma.
Results
Five meta-analyses were eligible for inclusion in the study. Eight variables (sex, tumour size, extrathyroidal extension, BRAF mutation, TERT mutation, histologic subtype, lymph node metastasis, and distant metastasis) were included. RSS1 was the best of the analysed models.
Conclusion
We developed and validated a new RSS derived from previous meta-analyses for patients with PTC. This RSS seems to be superior to previously published systems.

Citations

Citations to this article as recorded by

Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers
Devan Diwanji, Emmanuel Carrodeguas, Youngho Seo, Hyunseok Kang, Myat Han Soe, Janet M. Chiang, Li Zhang, Chienying Liu, Spencer C. Behr, Robert R. Flavell
Journal of Clinical Medicine.2024; 13(13): 3963. CrossRef
Investigating 18F-FDG PET/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review
Hongxi Wang, Hongyuan Dai, Qianrui Li, Guohua Shen, Lei Shi, Rong Tian
Frontiers in Oncology.2021;[Epub] CrossRef
Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma
Joohyun Woo, Hyeonkyeong Kim, Hyungju Kwon
Journal of Clinical Medicine.2021; 10(21): 5144. CrossRef

Review Article

Thyroid
Natural Killer Cells and Thyroid Diseases: Eun Kyung Lee, John B. Sunwoo; Endocrinol Metab. 2019;34(2):132-137. Published online June 24, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.2.132

8,051 View
114 Download
22 Web of Science
23 Crossref

Abstract PDF PubReader ePub

Abnormal production of thyroid hormone is one of the common endocrine disorders, and thyroid hormone production declines with age. The aging process also negatively affects the immune system. An interaction between endocrine system and the immune system has been proposed to be bidirectional. Emerging evidence suggests an interaction between a lymphocyte population, called natural killer (NK) cells and thyroid gland function. Here, we review the relationship between NK cells and thyroid function and disease.

Citations

Citations to this article as recorded by

A comprehensive analysis to reveal the underlying molecular mechanisms of natural killer cell in thyroid carcinoma based on single-cell RNA sequencing data
Xiaoqiong Li, Kejiang Wang, Jiaxin Liu, Yan Li
Discover Oncology.2025;[Epub] CrossRef
Natural Killer Cells in Graves’ Disease: Increased Frequency but Impaired Degranulation Ability Compared to Healthy Controls
Daniela Gallo, Eliana Piantanida, Raffaella Bombelli, Silvia Lepanto, Antonino Bruno, Matteo Gallazzi, Giorgia Bilato, Marina Borgese, Denisa Baci, Lorenzo Mortara, Maria Laura Tanda
International Journal of Molecular Sciences.2025; 26(3): 977. CrossRef
Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression
Eliza Turlej, Aleksandra Domaradzka, Justyna Radzka, Dominika Drulis-Fajdasz, Julita Kulbacka, Agnieszka Gizak
Cells.2025; 14(6): 403. CrossRef
Machine learning in lymphocyte and immune biomarker analysis for childhood thyroid diseases in China
Ruizhe Yang, Wei Li, Qing Niu, WenTao Yang, Wei Gu, Xu Wang
BMC Pediatrics.2025;[Epub] CrossRef
Tumor microenvironment in thyroid cancer: Immune cells, patterns, and novel treatments
Beatriz Febrero, Juan José Ruiz‐Manzanera, Inmaculada Ros‐Madrid, Antonio Miguel Hernández, Esteban Orenes‐Piñero, José Manuel Rodríguez
Head & Neck.2024; 46(6): 1486. CrossRef
Impact of Hashimoto’s thyroiditis on the tumor microenvironment in papillary thyroid cancer: insights from single-cell analysis
Hongzhe Ma, Guoqi Li, Diwei Huo, Yangguang Su, Qing Jin, Yangxu Lu, Yanyan Sun, Denan Zhang, Xiujie Chen
Frontiers in Endocrinology.2024;[Epub] CrossRef
Autoimmune Thyroid Disease and Pregnancy: The Interaction Between Genetics, Epigenetics and Environmental Factors
Tatjana Bogović Crnčić, Božena Ćurko-Cofek, Lara Batičić, Neva Girotto, Maja Ilić Tomaš, Antea Kršek, Ines Krištofić, Tea Štimac, Ivona Perić, Vlatka Sotošek, Sanja Klobučar
Journal of Clinical Medicine.2024; 14(1): 190. CrossRef
Thyroid hormones and minerals in immunocorrection of disorders in autoimmune thyroid diseases
Viktor Kravchenko, Tamara Zakharchenko
Frontiers in Endocrinology.2023;[Epub] CrossRef
New Insights into Immune Cells and Immunotherapy for Thyroid Cancer
Yujia Tao, Peng Li, Chao Feng, Yuan Cao
Immunological Investigations.2023; 52(8): 1039. CrossRef
Innate Immunity in Autoimmune Thyroid Disease during Pregnancy
Tatjana Bogović Crnčić, Neva Girotto, Maja Ilić Tomaš, Ines Krištofić, Sanja Klobučar, Lara Batičić, Božena Ćurko-Cofek, Vlatka Sotošek
International Journal of Molecular Sciences.2023; 24(20): 15442. CrossRef
Risk Factors Associated with Mortality among Patients with COVID-19: Analysis of a Cohort of 1213 Patients in a Tertiary Healthcare Center
Carlos Alfonso Romero-Gameros, Guadalupe Vargas-Ortega, Mario Enrique Rendón-Macias, Carlos Fredy Cuevas-García, Tania Colín-Martínez, Luis Alejandro Sánchez-Hurtado, Lourdes Josefina Balcázar-Hernández, Iván Emilio De la Cruz-Rodríguez, Enid Karina Pérez
Journal of Clinical Medicine.2022; 11(10): 2780. CrossRef
Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes
Camillo Bechi Genzano, Eugenia Bezzecchi, Debora Carnovale, Alessandra Mandelli, Elisa Morotti, Valeria Castorani, Valeria Favalli, Angela Stabilini, Vittoria Insalaco, Francesca Ragogna, Valentina Codazzi, Giulia Maria Scotti, Stefania Del Rosso, Benedet
Frontiers in Immunology.2022;[Epub] CrossRef
Long COVID and the Neuroendocrinology of Microbial Translocation Outside the GI Tract: Some Treatment Strategies
Adonis Sfera, Carolina Osorio, Sabine Hazan, Zisis Kozlakidis, Jose Campo Maldonado, Carlos Manuel Zapata-Martín del Campo, Jonathan J. Anton, Leah Rahman, Christina V. Andronescu, Garth L. Nicolson
Endocrines.2022; 3(4): 703. CrossRef
HS3ST3A1 and CAPN8 Serve as Immune-Related Biomarkers for Predicting the Prognosis in Thyroid Cancer
Zhao-Hui Chen, Hao-Ran Yue, Jun-Hui Li, Ruo-Yu Jiang, Xiao-Ning Wang, Xue-Jie Zhou, Yue Yu, Xu-Chen Cao, Rengyun Liu
Journal of Oncology.2022; 2022: 1. CrossRef
Construction of an Expression Classifier Based on an Immune-related Ten-gene Panel for Rapid Diagnosis of Papillary Thyroid Carcinoma Risks
Jingxue Sun, Jingjing Li, Yaguang Zhang, Jun Han, Jiaxing Wei, Yanmeizhi Wu, Bing Liu, Hongyu Han, Hong Qiao
Current Bioinformatics.2022; 17(10): 924. CrossRef
Papillary Thyroid Carcinoma Landscape and Its Immunological Link With Hashimoto Thyroiditis at Single-Cell Resolution
Jun Pan, Fang Ye, Chengxuan Yu, Qinsheng Zhu, Jiaqi Li, Yaohui Zhang, Hedi Tian, Yunjin Yao, Minjie Zhu, Yibin Shen, Feng Zhu, Yingying Wang, Xinhui Zhou, Guoji Guo, Yijun Wu
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
The Intriguing Thyroid Hormones–Lung Cancer Association as Exemplification of the Thyroid Hormones–Cancer Association: Three Decades of Evolving Research
Maria V. Deligiorgi, Dimitrios T. Trafalis
International Journal of Molecular Sciences.2021; 23(1): 436. CrossRef
Mass Cytometry Studies of Patients With Autoimmune Endocrine Diseases Reveal Distinct Disease-Specific Alterations in Immune Cell Subsets
Louise Magnusson, Hugo Barcenilla, Mikael Pihl, Sophie Bensing, Daniel Espes, Per-Ola Carlsson, Rosaura Casas
Frontiers in Immunology.2020;[Epub] CrossRef
Reduced proportion and activity of natural killer cells in patients with Graves’ disease
Qingqing Yang, Li Zhang, Cheng Guo, ChunJia Kou, Yu Long, Jianting Li, Hai-Qing Zhang
European Journal of Inflammation.2020; 18: 205873922094233. CrossRef
Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher
Daniela Gallo, Eliana Piantanida, Matteo Gallazzi, Luigi Bartalena, Maria Laura Tanda, Antonino Bruno, Lorenzo Mortara
Frontiers in Endocrinology.2020;[Epub] CrossRef
Quantitative and Functional Analysis of PD-1+ NK Cells in Patients With Autoimmune Thyroid Disease
Alma Cesleste Ortega-Rodríguez, Rebeca Martínez-Hernández, Adriana Monsiváis-Urenda, Ana Serrano-Somavilla, Raquel Sánchez-Gutiérrez, Roberto González-Amaro, Mónica Marazuela
The Journal of Clinical Endocrinology & Metabolism.2020; 105(11): e4001. CrossRef
Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment
Zhenyu Xie, Xin Li, Yuzhen He, Song Wu, Shiyue Wang, Jianjian Sun, Yuchen He, Yu Lun, Jian Zhang
Frontiers in Endocrinology.2020;[Epub] CrossRef
Immune and Inflammatory Cells in Thyroid Cancer Microenvironment
Silvia Martina Ferrari, Poupak Fallahi, Maria Rosaria Galdiero, Ilaria Ruffilli, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Armando Patrizio, Valeria Mazzi, Gilda Varricchi, Gianni Marone, Alessandro Antonelli
International Journal of Molecular Sciences.2019; 20(18): 4413. CrossRef

Original Article

Clinical Study
Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer: Myung-Chul Lee, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Guk Haeng Lee, Young Joo Park, Do Joon Park; Endocrinol Metab. 2019;34(2):150-157. Published online May 10, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.2.150

10,037 View
170 Download
35 Web of Science
38 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background

Thyroid-stimulating hormone (TSH) suppression is recommended for patients who undergo thyroidectomy for differentiated thyroid cancer (DTC). However, the impact of TSH suppression on clinical outcomes in low-risk DTC remains uncertain. Therefore, we investigated the effects of postoperative TSH levels on recurrence in patients with low-risk DTC after thyroid lobectomy.

Methods

Patients (n=1,528) who underwent thyroid lobectomy for papillary thyroid carcinoma between 2000 and 2012 were included in this study. According to the mean and dominant TSH values during the entire follow-up period or 5 years, patients were divided into four groups (<0.5, 0.5 to 1.9, 2.0 to 4.4, and ≥4.5 mIU/L). Recurrence-free survival was compared among the groups.

Results

During the 5.6 years of follow-up, 21 patients (1.4%) experienced recurrence. Mean TSH levels were within the recommended low-normal range (0.5 to 1.9 mIU/L) during the total follow-up period or 5 years in 38.1% or 36.0% of patients. The mean and dominant TSH values did not affect recurrence-free survival. Adjustment for other risk factors did not alter the results.

Conclusion

Serum TSH levels did not affect short-term recurrence in patients with low-risk DTC after thyroid lobectomy. TSH suppression should be conducted more selectively.

Citations

Citations to this article as recorded by

Effects of 131I and TSH suppression therapy on METTL3, METTL14 levels and recurrence in thyroid cancer
Li-Guo Yang
American Journal of Cancer Research.2025; 15(1): 42. CrossRef
Tailoring TSH suppression in differentiated thyroid carcinoma: evidence, controversies, and future directions
Xinxin Song, Xin Zhi, Linxue Qian
Endocrine.2025;[Epub] CrossRef
The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery
Iwao Sugitani, Naomi Kiyota, Yasuhiro Ito, Naoyoshi Onoda, Tomo Hiromasa, Kiyomi Horiuchi, Seigo Kinuya, Tetsuo Kondo, Sueyoshi Moritani, Kiminori Sugino, Hisato Hara
Endocrine Journal.2025; 72(5): 545. CrossRef
Dynamic risk assessment in patients with differentiated thyroid cancer
Erika Abelleira, Fernando Jerkovich
Reviews in Endocrine and Metabolic Disorders.2024; 25(1): 79. CrossRef
Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study
Xue Yin, Chao Lu, Danyang Sun, Yanhui Ji, Yan Wang, Hongyuan Zheng, Ziyu Ma, Qiang Jia, Jian Tan, Wei Zheng
Endocrine.2024; 84(3): 1064. CrossRef
Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung Lee, Eu Jeong Ku, Su-jin Kim, Woochul Kim, Jae Won Cho, Kyong Yeun Jung, Hyeong Won Yu, Yea Eun Kang, Mijin Kim, Hee Kyung Kim, Junsun Ryu, June Young Choi
Annals of Surgical Treatment and Research.2024; 106(1): 19. CrossRef
Impact of a mobile health intervention based on multi-theory model of health behavior change on self-management in patients with differentiated thyroid cancer: protocol for a randomized controlled trial
Yang Jiang, Xiangju Sun, Maomin Jiang, Hewei Min, Jing Wang, Xinghua Fu, Jiale Qi, Zhenjie Yu, Xiaomei Zhu, Yibo Wu
Frontiers in Public Health.2024;[Epub] CrossRef
Risk of Subsequent Primary Cancers in Thyroid Cancer Survivors according to the Dose of Levothyroxine: A Nationwide Cohort Study
Min-Su Kim, Jang Won Lee, Min Kyung Hyun, Young Shin Song
Endocrinology and Metabolism.2024; 39(2): 288. CrossRef
Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part II. Follow-up Surveillance after Initial Treatment 2024
Mijin Kim, Ji-In Bang, Ho-Cheol Kang, Sun Wook Kim, Dong Gyu Na, Young Joo Park, Youngduk Seo, Young Shin Song, So Won Oh, Sang-Woo Lee, Eun Kyung Lee, Ji Ye Lee, Dong-Jun Lim, Ari Chong, Yun Jae Chung, Chae Moon Hong, Min Kyoung Lee, Bo Hyun Kim
International Journal of Thyroidology.2024; 17(1): 115. CrossRef
An age-and sex-matched postoperative therapy should be required in thyroid papillary carcinoma
Caigu Yan, Jinjin Sun, Xianghui He, Lanning Jia
Frontiers in Endocrinology.2024;[Epub] CrossRef
Prognostic Implications of Maintaining the Target Thyroid-Stimulating Hormone Status Based on the 2015 American Thyroid Association Guidelines in Patients with Low-Risk Papillary Thyroid Carcinoma after Lobectomy: A 5-Year Landmark Analysis
Ye Won Jeon, Young Jin Suh, Seung Taek Lim
Cancers.2024; 16(19): 3253. CrossRef
The necessity of thyroid-stimulating hormone suppression therapy for low-risk differentiated thyroid carcinoma following hemithyroidectomy: A systematic review and meta-analysis
Xinyu Wang, Yuqian Ye, Mizaniya Amdulla, Chenglong Ren, Yunhe Liu, Song Ni
Heliyon.2024; 10(23): e40574. CrossRef
Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer
Arash Abiri, Khodayar Goshtasbi, Sina J. Torabi, Edward C. Kuan, William B. Armstrong, Tjoson Tjoa, Yarah M. Haidar
Otolaryngology–Head and Neck Surgery.2023; 168(4): 745. CrossRef
Outcomes of Patients with an Intermediate‐Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma
Kiyomi Horiuchi, Mikiko Fujimoto, Kamio Hidenori, Yusaku Yoshida, Eiichiro Noguchi, Yoko Omi, Takahiro Okamoto
World Journal of Surgery.2023; 47(10): 2464. CrossRef
Effects of Isthmus Preservation on Postoperative Hypothyroidism after Lobectomy
Yeong San Jeon, Wan Wook Kim
International Journal of Thyroidology.2023; 16(1): 120. CrossRef
Physical activity and reduced risk of fracture in thyroid cancer patients after thyroidectomy — a nationwide cohort study
Jinyoung Kim, Kyungdo Han, Jin-Hyung Jung, Jeonghoon Ha, Chaiho Jeong, Jun-Young Heu, Se-Won Lee, Jeongmin Lee, Yejee Lim, Mee Kyoung Kim, Hyuk-Sang Kwon, Ki-Ho Song, Ki-Hyun Baek
Frontiers in Endocrinology.2023;[Epub] CrossRef
Association between thyroid stimulating hormone levels and papillary thyroid cancer risk: A meta-analysis
Bin Xu, Shu-Yan Gu, Ning-Ming Zhou, Jun-Jie Jiang
Open Life Sciences.2023;[Epub] CrossRef
The Relationship between Thyrotropin Serum Concentrations and Thyroid Carcinoma
Xueqi Zhang, Lijun Tian, Di Teng, Weiping Teng
Cancers.2023; 15(20): 5017. CrossRef
Differentiated thyroid cancer: a focus on post-operative thyroid hormone replacement and thyrotropin suppression therapy
Benjamin J. Gigliotti, Sina Jasim
Endocrine.2023; 83(2): 251. CrossRef
Optimal Serum Thyrotropin Level for Patients with Papillary Thyroid Carcinoma After Lobectomy
Siyuan Xu, Ying Huang, Hui Huang, Xiaohang Zhang, Jiaxin Qian, Xiaolei Wang, Zhengang Xu, Shaoyan Liu, Jie Liu
Thyroid.2022; 32(2): 138. CrossRef
Optimal Thyrotropin Following Lobectomy for Papillary Thyroid Cancer: Does It Exist?
Lindsay Bischoff, Megan R. Haymart
Thyroid.2022; 32(2): 117. CrossRef
Evaluation of ITGA3 as a Biomarker of Progression and Recurrence in Papillary Thyroid Carcinoma
Guoliang Zhang, Bing Li, Yuanmei Lin
Frontiers in Oncology.2022;[Epub] CrossRef
The Question of an Optimal TSH Goal After Lobectomy for Papillary Thyroid Cancer
Bernadette Biondi
Clinical Thyroidology.2022; 34(2): 67. CrossRef
Is Maintaining Thyroid-Stimulating Hormone Effective in Patients Undergoing Thyroid Lobectomy for Low-Risk Differentiated Thyroid Cancer? A Systematic Review and Meta-Analysis
Ho-Ryun Won, Eonju Jeon, Jae Won Chang, Yea Eun Kang, Kunho Song, Sun Wook Kim, Dong Mee Lim, Tae Kwun Ha, Ki-Wook Chung, Hyo-Jeong Kim, Young Joo Park, Bon Seok Koo
Cancers.2022; 14(6): 1470. CrossRef
Research Review of Thermal Ablation in the Treatment of Papillary Thyroid Carcinoma
Di Ou, Chen Chen, Tian Jiang, Dong Xu
Frontiers in Oncology.2022;[Epub] CrossRef
CACA guidelines for holistic integrative management of thyroid cancer
Minghua Ge, Ming Gao, Ruochuan Cheng, Xiaohong Chen, Haixia Guan, Yansong Lin, Shaoyan Liu, Yu Wang, Chuanming Zheng, Xiangqian Zheng
Holistic Integrative Oncology.2022;[Epub] CrossRef
Value of thyroglobulin post hemithyroidectomy for cancer: a literature review
Saam S. Tourani, Bill Fleming, Justin Gundara
ANZ Journal of Surgery.2021; 91(4): 724. CrossRef
Pros and cons of hemi‐thyroidectomy for low‐risk differentiated thyroid cancer
Alexander J. Papachristos, Anthony Glover, Mark S. Sywak, Stan B. Sidhu
ANZ Journal of Surgery.2021; 91(9): 1704. CrossRef
Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review
Carla GAMBALE, Rossella ELISEI, Antonio MATRONE
Minerva Endocrinologica.2021;[Epub] CrossRef
The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study
Yi Dou, Yingji Chen, Daixing Hu, Xinliang Su
Frontiers in Endocrinology.2021;[Epub] CrossRef
Controversy: For or against thyroid lobectomy in > 1 cm differentiated thyroid cancer?
Fabrice Menegaux, Jean-Christophe Lifante
Annales d'Endocrinologie.2021; 82(2): 78. CrossRef
Thyroid cancer, recent advances in diagnosis and therapy
Fadi Nabhan, Priya H. Dedhia, Matthew D. Ringel
International Journal of Cancer.2021; 149(5): 984. CrossRef
A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
Eun Kyung Lee, Yea Eun Kang, Young Joo Park, Bon Seok Koo, Ki-Wook Chung, Eu Jeong Ku, Ho-Ryun Won, Won Sang Yoo, Eonju Jeon, Se Hyun Paek, Yong Sang Lee, Dong Mee Lim, Yong Joon Suh, Ha Kyoung Park, Hyo-Jeong Kim, Bo Hyun Kim, Mijin Kim, Sun Wook Kim, Ka
Endocrinology and Metabolism.2021; 36(3): 574. CrossRef
Long-term follow-up results of PTMC treated by ultrasound-guided radiofrequency ablation: a retrospective study
Yalin Zhu, Ying Che, Shuhang Gao, Shuangsong Ren, Mengying Tong, Lina Wang, Fang Yang
International Journal of Hyperthermia.2021; 38(1): 1225. CrossRef
Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up
Soo Young Kim, Hee Jun Kim, Seok-Mo Kim, Hojin Chang, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park
Frontiers in Endocrinology.2020;[Epub] CrossRef
Thyroid Lobectomy for Low to Intermediate Risk Differentiated Thyroid Cancer
Dana M. Hartl, Joanne Guerlain, Ingrid Breuskin, Julien Hadoux, Eric Baudin, Abir Al Ghuzlan, Marie Terroir-Cassou-Mounat, Livia Lamartina, Sophie Leboulleux
Cancers.2020; 12(11): 3282. CrossRef
Annual Neck Ultrasonography Surveillance between 3 to 12 Years after Thyroid Lobectomy for Papillary Thyroid Microcarcinoma
Jin Gu Kang, Jung Eun Choi, Soo Jung Lee, Su Hwan Kang
International Journal of Thyroidology.2020; 13(2): 142. CrossRef
Thyroid hormone therapy in differentiated thyroid cancer
Giorgio Grani, Valeria Ramundo, Antonella Verrienti, Marialuisa Sponziello, Cosimo Durante
Endocrine.2019; 66(1): 43. CrossRef

First
Prev
Page of 2
Next
Last

Search